Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $124
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $152 to $124.
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $152 to $124.